One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position Statement
doi : 10.1016/j.jchf.2026.103101
Volume 14, Issue 6, June 2026, 103101
Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial
doi : 10.1016/j.jchf.2025.102847
Volume 14, Issue 6, June 2026, 102847
Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization
doi : 10.1016/j.jchf.2025.102899
Volume 14, Issue 6, June 2026, 102899
Efficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF
doi : 10.1016/j.jchf.2026.102938
Volume 14, Issue 6, June 2026, 102938
Balancing Efficacy and Safety With Finerenone in Patients With Heart Failure and Chronic Kidney Disease
doi : 10.1016/j.jchf.2026.103063
Volume 14, Issue 6, June 2026, 103063
Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?
doi : 10.1016/j.jchf.2026.102946
Volume 14, Issue 6, June 2026, 102946
The Left Atrium: Heart Failure’s Silent “Memory” Across the Spectrum of Functional Mitral Regurgitation
doi : 10.1016/j.jchf.2026.103003
Volume 14, Issue 6, June 2026, 103003
Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance
doi : 10.1016/j.jchf.2026.102947
Volume 14, Issue 6, June 2026, 102947
Exercise-Induced Versus Resting Left Atrial Hypertension: 2 Phases or 2 Faces of HFpEF?
doi : 10.1016/j.jchf.2026.103004
Volume 14, Issue 6, June 2026, 103004
Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction: From Institutional Recognition to Clinical Integration
doi : 10.1016/j.jchf.2026.103046
Volume 14, Issue 6, June 2026, 103046
Targeting Inflammation in Heart Failure: Déjà Vu All Over Again or a Therapeutic Step Forward?
doi : 10.1016/j.jchf.2026.103049
Volume 14, Issue 6, June 2026, 103049
Engaging Patients and Clinicians With Remote Pulmonary Artery Pressures Monitoring Improves Care: The PROACTIVE-HF Clinical Trial
doi : 10.1016/j.jchf.2026.103008
Volume 14, Issue 6, June 2026, 103008
Hemodynamic Effects of Oral Ketone Ester in Acutely Decompensated Heart Failure With Low Cardiac Output Syndrome
doi : 10.1016/j.jchf.2025.102886
Volume 14, Issue 6, June 2026, 102886
From Fuel to Flow: Translating the Beneficial Hemodynamic Effects of Exogenous Ketones in the ICU
doi : 10.1016/j.jchf.2026.103047
Volume 14, Issue 6, June 2026, 103047
Higher Prevalence of Coronary Microvascular Dysfunction in Patients With HFpEF Without Obesity
doi : 10.1016/j.jchf.2025.102894
Volume 14, Issue 6, June 2026, 102894
Phenotyping HFpEF by Using Left Ventricular End-Diastolic Dimension and ITS Relationship With Postdischarge 1-Year Mortality
doi : 10.1016/j.jchf.2025.102895
Volume 14, Issue 6, June 2026, 102895
Efficacy of Alpha-Lipoic Acid in Patients With Ischemic Heart Failure: A Double-Blind, Randomized, Placebo-Controlled Study
doi : 10.1016/j.jchf.2025.102898
Volume 14, Issue 6, June 2026, 102898
Clinical Impact of Device-Based Multisensory Monitoring in Heart Failure: A Propensity-Matched Study From the Netherlands
doi : 10.1016/j.jchf.2025.102897
Volume 14, Issue 6, June 2026, 102897
Mind the Gap: Challenges Moving Trial Doses Into Practice
doi : 10.1016/j.jchf.2026.103051
Volume 14, Issue 6, June 2026, 103051
REPLY: Mind the Gap: Challenges Moving Trial Doses Into Practice
doi : 10.1016/j.jchf.2026.103052
Volume 14, Issue 6, June 2026, 103052
